BackShanghai Haohai Biological Technology , Ltd. Overview

Shanghai Haohai Biological Technology , Ltd. Receivables

Latest receivables for 688366.SS: $320M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$316.82M
↓ 24.72% YoYΔ $-104.04M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Haohai Biological Technology , Ltd. Receivables History

Loading

Shanghai Haohai Biological Technology , Ltd. vs. peers: Receivables Comparison

Loading

Shanghai Haohai Biological Technology , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Haohai Biological Technology , Ltd. (688366.SS) FAQ

Shanghai Haohai Biological Technology , Ltd.'s receivables stands at $320M as of September 2026. That compares with $420M in the prior-year period — down 24.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Shanghai Haohai Biological Technology , Ltd. reported $320M in receivables versus $420M a year earlier — a 24.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $420M in the prior-year period — down 24.7% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Shanghai Haohai Biological Technology , Ltd.'s receivables evolved across reporting periods, while the comparison chart places 688366.SS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Shanghai Haohai Biological Technology , Ltd.'s reading of $320M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.